**Name of journal:** ***World Journal of Gastroenterology***

**Manuscript NO: 42583**

**Manuscript type: ORIGINAL ARTICLE**

***Basic Study***

**Relationships among *KRAS* mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer**

Wan XB *et al*.*KRAS* gene and RAS pathway signaling molecules

Xiang-Bin Wan, Ai-Qin Wang, Jian Cao, Zhi-Chuang Dong, Ning Li, Sen Yang, Miao-Miao Sun, Zhi Li, Su-Xia Luo

**Xiang-Bin Wan, Jian Cao, Zhi-Chuang Dong, Zhi Li,** Department of General Surgery, the Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, Henan Province, China

**Ai-Qin Wang,** Department of Pharmacy, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, Henan Province, China

**Ning Li,Su-Xia Luo,** Department of Medical Oncology, the Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, Henan Province, China

**Sen Yang,** China-US (Henan) Hormel Cancer Institute, Zhengzhou 450008, China

**Miao-Miao Sun,** Department of Pathology, the Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, Henan Province, China

**ORCID number:** Xiang-Bin Wan (0000-0001-9855-9053); Ai-Qin Wang (0000-0001-8103-4832); Jian Cao (0000-0002-6781-1516); Zhi-Chuang Dong (0000-0003-3670-2517); Ning Li (0000-0001-8391-5772); Sen Yang (0000-0003-1449-5334); Miao-Miao Sun (0000-0001-9506-3749); Zhi Li (0000-0001-8651-1140); Su-Xia Luo (0000-0001-9541-2793).

**Author contributions:** Wan XB, Cao J, and Dong ZC collected and analyzed the data; Wan XB drafted the manuscript; Luo SX designed and supervised the study; Wang AQ, Li N, Yang S, Sun MM, and Li Z offered technical or material support; all authors have read and approved the final version to be published.

**Supported by**the Henan Department of Science and Technology, China, No. 162102310317.

**Institutional review board statement:** The study was approved by the Medical Ethics Committee of the Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, China, and all patients provided written informed consent.

**Conflict-of-interest statement:** The authors have no conflicts of interest to declare.

**Data sharing statement:** No additional data are available.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Corresponding author: Su-Xia Luo, MD, Professor,** Department of Medical Oncology, the Affiliated Tumor Hospital of Zhengzhou University, No. 127, Dongming Road, Jinshui District, Zhengzhou 450008, Henan Province, China. wxbzlyy@126.com

**Telephone:** +86-371-65961505

**Fax:** +86-371-65961505

**Received:** November 14, 2018

**Peer-review started:** November 14, 2018

**First decision:** December 5, 2018

**Revised:** January 17, 2019

**Accepted:** January 20, 2019

**Article in press:** January 20, 2019

**Published online:** February 21, 2019

**Abstract**

***BACKGROUND***

The RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathways all belong to mitogen-activated protein kinase (MAPK) signaling pathways, Mutations in any one of the upstream genes (such as the *RAS* gene or the *BRAF* gene) may be transmitted to the protein through transcription or translation, resulting in abnormal activation of the signaling pathway. This study investigated the relationship between the *KRAS* gene mutation and the clinicopathological features and prognosis of colorectal cancer (CRC), and the effect of *KRAS* mutations on its associated proteins in CRC, with an aim to clarify the cause of tumor progression and drug resistance caused by mutation of the *KRAS* gene.

***AIM***

To investigate the *KRAS* gene and RAS pathway signaling molecules in CRC and to analyze their relationship with clinicopathological features and prognosis

***METHODS***

Colorectal cancer tissue specimens from 196 patients were analyzed for *KRAS* mutations using quantitative polymerase chain reaction and for KRAS, BRAF, MEK, and ERK protein expression levels using immunohistochemistry of tumor microarrays. To analyze differences of RAS pathway signaling molecule expression levels in different *KRAS* gene status, the relationships between these parameters and clinicopathological features, 4-year progression-free survival, and overall survival were analyzed by independent sample *t* test, Kaplan-Meier plots, and the log-rank test. Predictors of overall and disease-free survival were assessed using a Cox proportional hazards model.

***RESULTS***

Of the 196 patients, 62 (32%) carried mutations in codon 12 (53/62) or codon 13 (9/62) in exon 2 of the *KRAS* gene. KRAS, BRAF, ERK, and MEK protein expression was detected in 71.4%, 78.8%, 64.3%, and 50.8% of CRC tissues, respectively. There were no significant differences between *KRAS* mutation status and KRAS, BRAF, MEK, or ERK protein levels. Positive expression of KRAS and ERK was associated with poor tumor differentiation, and KRAS expression was also associated with age < 56 years. MEK expression was significantly associated with distant metastasis (*P* < 0.05). The 4-year progression-free survival rate, but not overall survival rate, was significantly higher in patients with KRAS-negative tumors than in those with KRAS-positive tumors (*P* < 0.05), whereas BRAF, MEK, and ERK expression was unrelated to survival. Multivariate analysis showed that only the expression of KRAS protein was a risk factor for tumor recurrence (*P* < 0.05). No other clinicopathological factors correlated with KRAS, BRAF, MEK, or ERK expression.

***CONCLUSION***

*KRAS* gene mutations do not affect downstream protein expression in CRC. KRAS protein is associated with poor tumor differentiation, older age, and a risk of tumor recurrence.

**Key words:** Colorectal cancer; *KRAS* gene; KRAS protein; BRAF protein; MEK protein; ERK protein

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The RAS signaling pathway plays a crucial role in the invasiveness and metastasis of tumor cells. In this study, we examined the relationship between the *KRAS* gene mutation status and the clinicopathological features and prognosis of colorectal cancer (CRC) patients and the expression of BRAF, MEK, and ERK proteins. We found that *KRAS* gene mutations do not affect downstream protein expression or the clinicopathological features of CRC. KRAS protein is associated with poor tumor differentiation, older age, and a risk of tumor recurrence. The results may contribute to our understanding of drug resistance in *KRAS* mutant CRC.

**Citation:** Wan XB, Wang AQ, Cao J, Dong ZC, Li N, Yang S, Sun MM, Li Z, Luo SX. Relationships among *KRAS* mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer. *World J Gastroenterol* 2019; 25(7): 808-823

**URL:** https://www.wjgnet.com/1007-9327/full/v25/i7/808.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v25.i7.808

**INTRODUCTION**

Colorectal cancer (CRC) is the most common malignant tumor of the digestive system, and it ranks third in terms of incidence and mortality in both men and women in the United States[1]. According to the latest statistics, the estimated number of new CRC cases and deaths is expected to be 75610 and 27390, respectively, in American men and 64640 and 23240, respectively, in American women in 2018[1]. In China, the incidence of CRC in 2014 was 27.08/100000, and it is the fourth most common cancer among men and the third most common cancer among women[2]. In major Chinese cities, the incidence of CRC is even higher. In 2014, the incidence among men and women in Beijing was 44.12/100000 and 36.26/100000, respectively, and was the second and fourth most common cancer, respectively[3]. Improvements in the economy and living standards in China have increased both CRC morbidity and mortality.

CRC develops *via* a complex process involving multiple genes and signal transduction pathways[4,5]. Treatment of colonic cancer patients is highly dependent on the depth of tumor invasion (T-stage) as well as the extension of lymph node involvement (N-stage), which could be precisely evaluated today[6-11]. The main treatments include surgery, chemotherapy, and radiotherapy[12]. However, in recent years, several new drugs have been developed, most notably molecular targeted drugs, and the prognosis of CRC patients has greatly improved, especially those with advanced cancer. Nevertheless, resistance to targeted drugs is gradually increasing, and understanding the underlying mechanisms of tumor development and drug resistance has become increasingly important.

The RAS/RAF/MEK/ERK signaling pathway plays a crucial role in the proliferation, differentiation, survival, invasiveness, and metastasis of tumor cells[13-15]. This pathway is frequently abnormally activated in CRC, often due to mutations of upstream genes, such as *KRAS* and *BRAF,* that result in aberrant transcription or translation, leading to altered protein expression, activity, and/or signaling. In the present study, we examined the relationship between the *KRAS* gene mutation status and the clinicopathological features and prognosis of CRC patients. *KRAS* can be activated by many tumor-related proteins and is involved in their function as a network master[16,17]. We also investigated the effect of the *KRAS* genotype on the expression of BRAF, MEK, and ERK proteins. The results may contribute to our understanding of the underlying causes of tumor progression and drug resistance in *KRAS* mutant CRC[17].

**MATERIALS AND METHODS**

***Patients***

Tissue samples and clinical data (including gender, age at disease onset, tumor site, metastasis site, and tumor differentiation and stage) were collected from 220 CRC patients receiving treatment at the Affiliated Tumor Hospital of Zhengzhou University from January 2012 to December 2013. The average and median age of the patients was 58.4 and 56 years, respectively (range 18-84 years). All patients had complete case data and were followed for 10-58 mo, during which 49 patients died (Table 1). The study was approved by the Medical Ethics Committee of the Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, China, and all patients provided written informed consent.

***Real-time quantitative polymerase chain reaction (qPCR)***

Formalin-fixed paraffin-embedded (FFPE) tissue samples were sectioned (3-5 μm thick) and deparaffinized through a series of xylene and ethanol solutions using standard procedures[18]. DNA was extracted from the sections using a QIAamp DNA FFPE tissue kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. DNA was purified by ethanol precipitation, dissolved in distilled water, and analyzed for concentration and purity using a spectrophotometer (OD260/OD280 = 1.8 ± 0.2, OD260/OD230 ≥ 1.7). The total yield per sample was > 50 ng.

The *KRAS* gene mutation status was analyzed by real-time qPCR using a Human KRAS Gene Mutation Detection Kit (Beijing ACCB Biotech Ltd., Beijing, China). Pre-denaturation was performed at 95 ℃ for 10 min, followed by 40 cycles of denaturation at 95 ℃ for 15 s and annealing and extension at 60 ℃ for 60 s. If the Ct value was ≤ 38 in the FAM channel, the sample was considered to be *KRAS* mutation positive; if there was no amplification, the sample was considered mutation negative; if the Ct values were between 30 and 40, the experiment was repeated; and if the same result was obtained, the sample was defined as mutation status uncertain. The mutation site was identified from the fluorescence quantitation curve (Figure 1, Table 2).

***Tissue microarray and*** ***immunohistochemistry (IHC)***

A personal tissue arrayer (Beecher Instruments, Sun Prairie, WI, United States) with a perforated needle of 0.6-mm diameter was used to remove small cylinders from the primary tumor blocks, and they were then placed in an empty ‘recipient’ paraffin block. Two blocks were constructed containing a total of 220 tissue sections, each separated by 1 mm[19,20]. KRAS, BRAF, ERK, and MEK proteins were detected using primary antibodies from Abcam (Cambridge, United Kingdom) and a polymer detection MaxVision/HRP kit (Fuzhou Maixin Biotechnology Development Co., Ltd., Fuzhou, China). Incubation with anti-KRAS (diluted 1:2400), anti-NRAS (1:500), and anti-phospho-MEK1/2 (Ser221; 1:50) lasted for 30 min at room temperature. Incubation with anti-PI3K (p110δa/p85α, 1:400), anti-BRAF (1:50), and anti-phospho-p44/42 MAPK (ERK1/2, Thr202/Tyr204; 1:400) lasted for 60 min at room temperature. For the positive control, a human breast cancer tissue sample was stained with the same antibodies. For the negative control, the primary antibodies were substituted with phosphate-buffered saline (PBS).

***Histochemistry score***

KRAS, BRAF, ERK, and MEK protein expression was visualized as brown/yellow particles in the cytoplasm or cell membrane. To evaluate expression, we used a semi-quantitative histochemistry score (H-score)[21] based on a combination of the percentage of cells positively stained (0 points, 0-4%; 1, 5%-24%; 2, 25%-49%; 3, 50%-74%; and 4, >75%) and staining intensity (0 points, no color; 1, light yellow; 2, yellow; and 3, brown/yellow). The H-score = ΣPI(I+1), where PI represents the percentage of positive cells and I represents color intensity. The number of positive cells in each section and their staining intensity were converted into the corresponding values.

***Statistical analysis***

Analyses were performed using SPSS version 20.0 (IBM Corporation, Armonk, NY, United States). A *χ²* test was used to analyze the relationship between the *KRAS* gene mutation status and protein expression in CRC tissues. Correlations between clinicopathological parameters and protein expression were evaluated using Fisher’s exact test. Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan-Meier method and the log-rank test. A Cox proportional hazards model was applied to identify predictors of OS and disease-free survival. A *P*-value < 0.05 was considered significant.

**RESULTS**

Of the 220 samples originally obtained, 194-196 were successfully processed by IHC. Therefore, the number of cases available for statistical analysis was 194-196. Of the 196 CRC patients, 62 (31.6%) carried a *KRAS* mutation in the 12th codon (53/62) or 13th codon (9/62) of exon 2. The 12th codon mutations included GGT→GTT (24 cases), GGT→GAT (21 cases), GGT→GCT (6 cases), and GGT →TGT (2 cases). All nine mutations in the 13th codon were GGC→GAC (Figure 1).

***Relationships between KRAS, BRAF, MEK, and ERK protein expression and clinicopathological features of CRC patients***

The expression of KRAS, BRAF, MEK, and ERK proteins was detected by IHC (Figure 2). Of the 194-196 CRC tissues examined, 71.4% (140/196) stained positively for KRAS, 78.8% (153/194) for BRAF, 64.3% (126/196) for MEK, and 50.8% (99/195) for ERK. The expression of KRAS or ERK was associated with poor tumor differentiation (*P* < 0.05), and KRAS was also associated with age < 56 years (*P* < 0.05). MEK protein expression was positively associated with distant metastasis (*P* < 0.05; Tables 3 and 4).

***Relationship between KRAS genotype and KRAS protein expression***

IHC analysis indicated that KRAS protein was expressed in both the cytoplasm and cell membrane of CRC cells, but the majority was membrane localized. H-scores for KRAS protein IHC staining in the cell membrane were 133.4 ± 4.974 (*n* = 134) and 131.7 ± 5.091 (*n* = 134) for patients with mutant and wild-type *KRAS,* respectively, whereas the cytoplasmic scores were 59.76 ± 4.298 (*n* = 62) and 60.16 ± 3.354 (*n* = 133), respectively. These scores were not significantly different (Figures 3 and 4).

***Relationship between KRAS genotype and downstream protein expression in CRC*** ***tissues***

BRAF, MEK, and ERK proteins were expressed in 74.6%, 54.8%, and 45.2%, respectively, of *KRAS* mutant CRC tissues and in 74.2%, 58.2%, and 54.1%, respectively, of *KRAS* wild-type tissues. These differences were not statistically significant (Table 5).

The H-scores for BRAF, MEK, and ERK protein IHC staining were 64.07 ± 4.898, 36.50 ± 2.770, and 16.09 ± 2.318, respectively, in *KRAS* mutant CRC tissues, respectively (*n* = 134), and 55.25 ± 2.915, 33.74 ± 4.113, and 14.36 ± 3.379, respectively, in *KRAS* wild-type tissues (*n* = 62). These differences were not statistically significant (Figures 5-7).

***Relationship between the expression of KRAS and downstream proteins in CRC tissues***

BRAF, MEK, and ERK protein expression was positive in 76.4%, 78.6%, and 69.6%, respectively, of KRAS protein-positive CRC tissues and in 69.6%, 8.6%, and 39.3%, respectively, of KRAS protein-negative tissues. MEK and ERK expression was significantly more common in KRAS-positive tissues than in KRAS-negative tissues (*P* < 0.05; Table 6).

***Relationship between the expression of BRAF, MEK, and ERK in CRC******tissues***

MEK and ERK proteins were expressed in 67.5% and 52.7%, respectively, of BRAF-positive tissues and in 46.0% and 60.0%, respectively, of BRAF-negative tissues. These differences were not significant (Table 7). ERK was expressed in 57.9% (73/126) of MEK-positive tissues and 38.6% (27/70) of MEK-negative tissues, with a significant difference (*P* < 0.05).

***Relationship between KRAS, BRAF, MEK, and ERK protein******expression and prognosis for patients with stage II/III CRC***

The 4-year PFS rates for stage II/III CRC patients with positive *vs* negative protein expression were 77.78% *vs* 90.29% (*P* = 0.0411) for KRAS, 83.33% *vs* 87.5% (*P* = 0.4395) for BRAF, 85% *vs* 87.50% (*P* = 0.6768) for MEK, and 85.71% *vs* 87.32% (*P* = 0.7657) for ERK. The 4-year OS rates for the same groups were 89.32% *vs* 93.33% (*P* = 0.4555) for KRAS, 86.11% *vs* 89.26% (*P* = 0.3109) for BRAF, 89.77% *vs* 91.67% (*P* = 0.6768) for MEK, and 88.31% *vs* 92.96% (*P* = 0.3380) for ERK. Only the 4-year PFS rates of the KRAS protein-positive and -negative groups were significantly different (*P* = 0.0411; Figure 8).

***Multivariate analysis of the prognostic significance of KRAS, BRAF, MEK, and ERK expression in stage II/III CRC patients***

Multivariate analysis showed that only positive KRAS protein expression was a risk factor for disease recurrence in patients with stage II/III CRC. The risk was 3.319-fold higher for KRAS-positive than KRAS-negative patients (95% confidence interval: 1.231-8.944; Tables 8 and 9).

**DISCUSSION**

The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor that activates downstream effector proteins *via* the RAS/RAF/MEK/ERK pathway. Previous work found that the *KRAS* gene mutation status correlated with the clinical efficacy of anti-EGFR antibody therapies[22-24], and that only wild-type KRAS tumors benefited from such therapy.

The *KRAS* gene, which is located on chromosome 12, is composed of four coding exons and one 5′ non-coding exon and produces a 21 kDa protein composed of 189 amino acids. Members of the RAS superfamily, including KRAS, have similar molecular structures and bind guanine nucleotides. RAS continuously cycles through active (GTP bound) and inactive (GDP bound) conformational states. The binary behavior of these proteins allows them to act as molecular switches in signaling processes. In this manner, the mutant *KRAS* gene results in a constitutively active GTP-bound state and the activation of downstream pro-proliferative signaling pathways[25,26]. The most common oncogenic mutations in CRCs are point mutations at positions 12, 13, and 61 of *KRAS*, with approximately 90% being in codons 12 and 13[22-27]. These amino acid mutations impair GTPase hydrolase activity and maintain the protein in an activated state, which results in continuous signaling to downstream effectors, even in the absence of extracellular stimulation. In our study, we detected a *KRAS* mutation rate of 30.9%, which is consistent with previous reports of 30%-40% in China[28] and was lower than those (30%-50%) observed in other countries[27,29-31].

To date, few studies have examined the relationship between *KRAS* genotype and protein expression. We found that KRAS protein was expressed in 55.8% of *KRAS* mutant tissues and in 44.2% of *KRAS* wild-type tissues, and the difference was not significant. The KRAS protein level, as measured using the semi-quantitative H-score, was also not significantly different between patients with mutant or wild-type *KRAS* tumors. Thus, there appears to be no obvious relationship between the *KRAS* mutation status and the expression level of KRAS protein. In addition to binding to GTP, RAS proteins must associate with cellular membranes in order to transduce signals[32-34]. We also found that the *KRAS* genotype had no effect on the distribution of KRAS protein between the cell membrane and cytoplasm. These data suggest that activation of KRAS or its downstream pathway components is unrelated to the expression level or subcellular location of KRAS protein.

Unfortunately, *KRAS* gene mutations account for approximately 35% of the nonresponsive patients who receive anti-EGFR treatment[35]. Therefore, using the *KRAS* gene as a predictor of clinical outcome is not always useful. We also examined the frequency and level of BRAF, MEK, and ERK expression in tissues expressing mutant or wild-type *KRAS*. We detected no effects of the *KRAS* genotype on the expression of any of these proteins. However, MEK and ERK expression was significantly more common in KRAS protein-positive tumors than in KRAS-negative tumors. Similarly, ERK expression was significantly more common in the MEK-positive than in the MEK-negative group of tumors. Thus, increased expression of an upstream protein can elevate the expression of a downstream protein in the same signaling pathway. ERK is the sole substrate of MEK in the RAS/RAF/MEK/ERK signaling pathway and their expression levels are often similar[36].

BRAF protein is mainly activated *via* two mechanisms: upstream RAS signaling or mutation of *BRAF*. The *BRAF* gene mutation status is also correlated with the clinical efficacy of anti-EGFR antibody therapies[37]. BRAF protein is phosphorylated and activated, and BRAF in turn phosphorylates MEK1/MEK2, which activates ERK and promotes its entry into the nucleus to regulate gene expression. The *BRAF* gene is also mutated in many cancers[38]. Kadowaki *et al*[39] found a 4%-10% *BRAF* mutation rate in CRC patients, whereas the mutation rate can be as high as 90% in sigmatic serrated adenoma[40]. Little is known about BRAFprotein expression in CRC tissue. We found that 78.8% of our CRC tumor specimens were positive for BRAF protein, but the frequency and level were not significantly different in samples from *KRAS* mutant and wild-type tissues. It is possible that the BRAF protein expression is high in both adenoma and carcinoma tissues.

Tumor stage, the most important factor affecting prognosis, is mainly based on the depth of tumor invasion, lymph node metastasis, and distant metastasis. The prognostic significance of KRAS, BRAF, MEK, and ERK protein expression in CRC tissues has not been investigated. In this study, we analyzed the 4-year PFS and OS rates according to KRAS, BRAF, MEK, and ERK positive or negative expression in patients with stage II/III cancer. Multivariate analysis showed that only KRAS protein expression was a risk factor for recurrence, suggesting that it could be used as a predictive marker for prognosis in CRC.

In summary, our data suggest that only using the *KRAS* gene as a predictor of clinical outcome is not enough, and combined detection of intracellular signal transduction pathways may advance our understanding of the development and treatment of tumors, including CRC.

**Article Highlights**

***Research background***

The RAS signaling pathway plays a crucial role in the invasiveness and metastasis of tumor cells. Mutations in any one of the upstream genes (such as the *RAS* gene) may be transmitted to the protein through transcription or translation, resulting in abnormal activation of the signaling pathway. Patients with *KRAS* gene mutation have a poor prognosis. This study investigated the effect of *KRAS* mutations on its associated proteins in colorectal cancer. It is helpful to understand the cause of tumor progression and drug resistance caused by mutation of the *KRAS* gene.

***Research motivation***

By analyzing the effect of upstream gene mutation on the downstream protein expression of signal pathway, it is helpful to further understand the cause of drug resistance. Future studies should focus on the active forms and structures of signal molecules, and find out which forms and conformational proteins are active, which is conducive to the synthesis of corresponding targeted drugs.

***Research objectives***

The main goal was to find out which forms and conformational proteins are active. At present, it is found that the amount of protein is not the main factor affecting the activity. Achieving these goals can help to develop targeted therapies.

***Research methods***

In this study, the mutation of the *KRAS* gene was analyzed by real-time quantitative polymerase chain reaction, protein expression was analyzed by immunohistochemistry, and the impact of gene mutation on protein expression, the effect of gene and protein on prognosis, and the relationship between protein expression and clinicopathology were analyzed.

***Research results***

*KRAS* gene status had no significant effect on RAS pathway signaling molecules in colorectal cancer. Positive expression of KRAS and ERK was associated with poor tumor differentiation. MEK expression was associated with more distant metastasis. The 4-year progression-free survival rate was significantly higher in patients with KRAS-negative tumors than in those with KRAS-positive tumors. Multivariate analysis showed that only the expression of KRAS protein was a risk factor for tumor recurrence. These results are consistent with observations in clinical practice, indicating the credibility of the study. The specific reasons for the genetic and protein effects of these results need to be further clarified.

***Research conclusions***

In this study, the relationship between the *KRAS* gene and the RAS signaling pathway molecule was discussed. It was found that the gene-to-protein to functional change was a complex process, and the gene mutation did not cause an increase in the positive rate of downstream protein expression. KRAS protein was found to be involved in tumor differentiation and prognosis. The study also found that the farther apart the molecules in the signal pathway, the smaller the effect, suggesting that the signaling pathways are intertwined. The combination of targeted drugs and multi-channel blockade is better than single-channel blockade.

***Research perspectives***

The study began without considering the phosphorylation of the signal molecule and the effect of structure on function. Future research is best to study the effect of phosphorylation and spatial structure changes of a certain signal molecule on function. Using atomic force microscopy and mass spectrometry and cryo-electron microscopy equipment and electron microscopy negative staining preparation methods to observe the spatial structure of individual lipoprotein molecules can find which conformational proteins are active.

**REFERENCES**

1 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin* 2018; 68: 7-30 [PMID: 29313949 DOI: 10.3322/caac.21442]

2 **Yang L,** Zheng R, Wang N, Yuan Y, Liu S, Li H, Zhang S, Zeng H, Chen W. Incidence and mortality of stomach cancer in China, 2014. *Zhongguo Aizheng Yanjiu* 2018; **30**: 291-298

3 **Liu S**, Yang L, Yuan Y, Li H, Tian J, Lu S, Wang N, Ji J. Cancer incidence in Beijing, 2014. *Chin J Cancer Res* 2018; **30**: 13-20 [PMID: 29545715 DOI: 10.21147/j.issn.1000-9604.2018.01.02]

4 **Dienstmann R**, Elez E, Argiles G, Matos I, Sanz-Garcia E, Ortiz C, Macarulla T, Capdevila J, Alsina M, Sauri T, Verdaguer H, Vilaro M, Ruiz-Pace F, Viaplana C, Garcia A, Landolfi S, Palmer HG, Nuciforo P, Rodon J, Vivancos A, Tabernero J. Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights. *Mol Oncol*2017; **11**: 1263-1272 [PMID: 28618197 DOI: 10.1002/1878-0261.12099]

5 **De Luca A**, Maiello MR, D'Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. *Expert Opin Ther Targets* 2012; **16** Suppl 2: S17-S27 [PMID: 22443084 DOI: 10.1517/14728222.2011.639361]

6 **Malmstrøm ML**, Săftoiu A, Vilmann P, Klausen TW, Gögenur I. Endoscopic ultrasound for staging of colonic cancer proximal to the rectum: A systematic review and meta-analysis. *Endosc Ultrasound* 2016; **5**: 307-314 [PMID: 27803903]

7 **Castro-Pocas FM**, Dinis-Ribeiro M, Rocha A, Santos M, Araújo T, Pedroto I. Colon carcinoma staging by endoscopic ultrasonography miniprobes. *Endosc Ultrasound* 2017; **6**: 245-251 [PMID: 28663528 DOI: 10.4103/2303-9027.190921]

8 **Ignee A**, Dong Y, Schuessler G, Baum U, Dietrich CF. Endorectal fusion imaging: A description of a new technique. *Endosc Ultrasound* 2017; **6**: 241-244 [PMID: 28685744 DOI: 10.4103/2303-9027.209868]

9 **Wang Y**, Zhou Y, Hu Z. The Functions of Circulating Tumor Cells in Early Diagnosis and Surveillance During Cancer Advancement. *J Transl Int Med* 2017; **5**: 135-138 [PMID: 29085785 DOI: 10.1515/jtim-2017-0029]

10 **Wu D**, Li JN, Qian JM. Endoscopic Diagnosis and Treatment of Precancerous Colorectal Lesions in Patients with Inflammatory Bowel Disease: How Does the Latest SCENIC International Consensus Intersect with Our Clinical Practice? *J Transl Int Med* 2017; **5**: 4-7 [PMID: 28680833 DOI: 10.1515/jtim-2017-0008]

11 **Okasha HH**, Naguib M, El Nady M, Ezzat R, Al-Gemeie E, Al-Nabawy W, Aref W, Abdel-Moaty A, Essam K, Hamdy A. Role of endoscopic ultrasound and endoscopic-ultrasound-guided fine-needle aspiration in endoscopic biopsy negative gastrointestinal lesions. *Endosc Ultrasound* 2017; **6**: 156-161 [PMID: 28621291 DOI: 10.4103/2303-9027.201086]

12 **Ersan V**, Kutlu R, Erdem C, Karagul S, Kayaalp C. Colorectal Stenting for Obstruction due to Retrorectal Tumor in a Patient Unsuitable for Surgery. *J Transl Int Med* 2017; **5**: 186-188 [PMID: 29164050 DOI: 10.1515/jtim-2017-0026]

13 **Ciardiello F**, Tortora G. EGFR antagonists in cancer treatment. *N Engl J Med* 2008; **358**: 1160-1174 [PMID: 18337605 DOI: 10.1056/NEJMra0707704]

14 **Qing H**, Gong W, Che Y, Wang X, Peng L, Liang Y, Wang W, Deng Q, Zhang H, Jiang B. PAK1-dependent MAPK pathway activation is required for colorectal cancer cell proliferation. *Tumour Biol* 2012; **33**: 985-994 [PMID: 22252525 DOI: 10.1007/s13277-012-0327-1]

15 **Levidou G**, Saetta AA, Gigelou F, Karlou M, Papanastasiou P, Stamatelli A, Kavantzas N, Michalopoulos NV, Agrogiannis G, Patsouris E, Korkolopoulou P. ERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics. *World J Surg Oncol* 2012; **10**: 47 [PMID: 22376079 DOI: 10.1186/1477-7819-10-47]

16 **Zhao SL**, Hong J, Xie ZQ, Tang JT, Su WY, Du W, Chen YX, Lu R, Sun DF, Fang JY. TRAPPC4-ERK2 interaction activates ERK1/2, modulates its nuclear localization and regulates proliferation and apoptosis of colorectal cancer cells. *PLoS One* 2011; **6**: e23262 [PMID: 21826244 DOI: 10.1371/journal.pone.0023262]

17 **Su N**, Peng L, Xia B, Zhao Y, Xu A, Wang J, Wang X, Jiang B. Lyn is involved in CD24-induced ERK1/2 activation in colorectal cancer. *Mol Cancer* 2012; **11**: 43 [PMID: 22731636 DOI: 10.1186/1476-4598-11-43]

18 **Bonin S**, Groenen PJTA, Halbwedl I, Popper HH. DNA Extraction from Formalin-Fixed Paraffin-Embedded (FFPE) Tissues. In: Guidelines for Molecular Analysis in Archive Tissues. Springer Berlin Heidelberg, 2011 [DOI: 10.1007/978-3-642-17890-0\_7]

19 **Kononen J**, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. *Nat Med* 1998; **4**: 844-847 [PMID: 9662379]

20 **Battifora H**. The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. *Lab Invest* 1986; **55**: 244-248 [PMID: 3525985]

21 **Budwit-Novotny DA**, McCarty KS, Cox EB, Soper JT, Mutch DG, Creasman WT, Flowers JL, McCarty KS Jr. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. *Cancer Res* 1986; **46**: 5419-5425 [PMID: 3756890]

22 **Brink M**, de Goeij AF, Weijenberg MP, Roemen GM, Lentjes MH, Pachen MM, Smits KM, de Bruïne AP, Goldbohm RA, van den Brandt PA. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. *Carcinogenesis* 2003; **24**: 703-710 [PMID: 12727799]

23 **Karapetis CS**, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med* 2008; **359**: 1757-1765 [PMID: 18946061 DOI: 10.1056/NEJMoa0804385]

24 **Amado RG**, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol* 2008; **26**: 1626-1634 [PMID: 18316791 DOI: 10.1200/JCO.2007.14.7116]

25 **Bos JL**. ras oncogenes in human cancer: a review. *Cancer Res* 1989; **49**: 4682-4689 [PMID: 2547513]

26 **Schubbert S**, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. *Nat Rev Cancer* 2007; **7**: 295-308 [PMID: 17384584 DOI: 10.1038/nrc2109]

27 **Tanioka H**, Asano M, Yoshida R, Waki N, Uno F, Ishizaki M, Yamashita K, Morishita Y, Nagasaka T. Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study. *Oncol Lett* 2018; **16**: 3674-3680 [PMID: 30127977 DOI: 10.3892/ol.2018.9127]

28 **Pu XX**, Deng YH, Xu F, Xiao J, Guo HQ, Huang H, Tian Y, He YJ, Lin TY. [Effect of KRAS mutation on efficacy of Cetuximab combined with chemotherapy in advanced colorectal cancer patients]. *Zhonghua Wei Chang Wai Ke Za Zhi* 2009; **12**: 594-597 [PMID: 19921572]

29 **Sundström M**, Edlund K, Lindell M, Glimelius B, Birgisson H, Micke P, Botling J. KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice. *BMC Cancer* 2010; **10**: 660 [PMID: 21122130 DOI: 10.1186/1471-2407-10-660]

30 **Bokemeyer C**, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. *J Clin Oncol* 2009; **27**: 663-671 [PMID: 19114683 DOI: 10.1200/JCO.2008.20.8397]

31 **Peeters M**, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. *J Clin Oncol* 2010; **28**: 4706-4713 [PMID: 20921462 DOI: 10.1200/JCO.2009.27.6055]

32 **Philips MR**. Compartmentalized signalling of Ras. *Biochem Soc Trans* 2005; **33**: 657-661 [PMID: 16042567 DOI: 10.1042]

33 **Liang H**, Gorfe A, Hancock JF, Zhou Y. Lipid-anchored ras proteins sense/modulate plasma membrane curvature in an isoform-specific manner. *Biophysical J* 2018; **114**: 73a-74a [DOI: 10.1016/j.bpj.2017.11.449]

34 **Ahearn IM**, Haigis K, Bar-Sagi D, Philips MR. Regulating the regulator: post-translational modification of RAS. *Nat Rev Mol Cell Biol* 2011; **13**: 39-51 [PMID: 22189424 DOI: 10.1038/nrm3255]

35 **Allegra CJ**, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. *J Clin Oncol* 2009; **27**: 2091-2096 [PMID: 19188670 DOI: 10.1200/JCO.2009.21.9170]

36 **Castellano E**, Downward J. RAS Interaction with PI3K: More Than Just Another Effector Pathway. *Genes Cancer* 2011; **2**: 261-274 [PMID: 21779497 DOI: 10.1177/1947601911408079]

37 **Van Cutsem E**, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. *J Clin Oncol* 2011; **29**: 2011-2019 [PMID: 21502544 DOI: 10.1200/JCO.2010.33.5091]

38 **Lavoie H**, Therrien M. Regulation of RAF protein kinases in ERK signalling. *Nat Rev Mol Cell Biol* 2015; **16**: 281-298 [PMID: 25907612 DOI: 10.1038/nrm3979]

39 **Kadowaki S**, Kakuta M, Takahashi S, Takahashi A, Arai Y, Nishimura Y, Yatsuoka T, Ooki A, Yamaguchi K, Matsuo K, Muro K, Akagi K. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. *World J Gastroenterol* 2015; **21**: 1275-1283 [PMID: 25632202 DOI: 10.3748/wjg.v21.i4.1275]

40 **Carr NJ**, Mahajan H, Tan KL, Hawkins NJ, Ward RL. Serrated and non-serrated polyps of the colorectum: their prevalence in an unselected case series and correlation of BRAF mutation analysis with the diagnosis of sessile serrated adenoma. *J Clin Pathol* 2009; **62**: 516-518 [PMID: 19126563 DOI: 10.1136/jcp.2008.061960]

**P-Reviewer:** Haneder S, Mangiola F, Sun K

**S-Editor:** Ma RY **L-Editor:** Wang TQ **E-Editor:** Huang Y

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Clinicopathological features of the 220 colorectal patients included in this study**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Patient characteristic** | **Number of patients** | **(%)** |
| Gender | Male | 113 | 51.3 |
|  | Female | 107 | 48.6 |
| Median age (yr) | <56 | 17 | 7.7 |
|  | ≥56 | 76 | 34.5 |
| Tumor site | Right colon | 45 | 20.5 |
|  | Left colorectum | 175 | 79.5 |
| Differentiation | Moderate-low | 143 | 65 |
|  | Well | 77 | 35 |
| Infiltration depth | T1 | 13 | 5.9 |
|  | T2 | 29 | 13.2 |
|  | T3 | 86 | 39.1 |
|  | T4 | 92 | 41.8 |
| Lymph node metastasis | N1-N3 | 118 | 53.6 |
|  | N0 | 102 | 46.4 |
| TNM stage | I | 35 | 15.9 |
|  | II | 62 | 28.2 |
|  | III | 73 | 33.2 |
|  | IV | 50 | 22.7 |

**Table 2 Identification of *KRAS* mutations**

|  |  |  |  |
| --- | --- | --- | --- |
| **Position** | **Code name** | ***KRAS* gene allele site** | **Signal channel** |
| A | IR | IR gene FAM | FAM |
| B | KM1 | Exon 12, 34G>T mutation (G12C) FAM, HEX | FAM, HEX |
| C | KM2 | Exon 12, 34G>A mutation (G12S) FAM, HEX | FAM, HEX |
| D | KM3 | Exon 12, 34G>C mutation (G12R) FAM, HEX | FAM, HEX |
| E | KM4 | Exon 12, 35G>T mutation (G12V) FAM, HEX | FAM, HEX |
| F | KM5 | Exon 12, 35G>A mutation (G12D) FAM, HEX | FAM, HEX |
| G | KM6 | Exon 12, 35G>C mutation (G12A) FAM, HEX | FAM, HEX |
| H | KM7 | Exon 13, 38G>A mutation (G13D) FAM, HEX | FAM, HEX |

**Table 3 Relationship between KRAS and BRAF protein expression and clinicopathological features of colorectal cancer patients**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **General data** |  | **KRAS protein** | | | | **BRAF protein** | | |
|  | **Positive rate (%)** | ***χ²*** | | ***P*-value** | **Positive rate (%)** | ***χ²*** | ***P-*value** |
| Median age (yr) | <56 | 71 (57/80) | | 5.34 | 0.02 | 77.6 (52/67) | 0.10 | 0.76 |
| ≥56 | 65.9 (83/126) | | 79.5 (101/127) |
| Gender | Male | 74.3 (84/123) | | 1.11 | 0.29 | 79.5 (89/112) | 0.06 | 0.81 |
| Female | 64.5 (56/83) | | 78.0 (64/82) |
| Differentiation | Medium-low | 71.6 (106/148) | | 10.8 | 0.001 | 75.7 (106/140) | 3.23 | 0.08 |
| Well | 70.8 (34/48) | | 87.0 (47/54) |
| Infiltration depth | T1+T2 | 63.2 (24/38) | | 0.21 | 1.52 | 79.9 (111/139) | 0.28 | 0.59 |
| T3+T4 | 73.4 (116/158) | | 76.4 (42/55) |
| Lymph node metastasis | N0 | 69.6 (64/92) | | 0.29 | 0.59 | 75.0 (69/92) | 0.024 | 0.878 |
| N1-N3 | 73.1 (76/104) | | 74.0 (77/104) |
| Distant metastasis | M0 | 70.2 (106/151) | | 0.49 | 0.49 | 75.9 (107/141) | 2.96 | 0.10 |
| M1 | 75.6 (34/45) | | 86.8 (46/53) |
| TNM stage | Stage I | 64 (16/25) | | 0.79 | 0.85 | 75.0 (18/24) | 5.98 | 0.11 |
| Stage II | 71.9 (41/57) | | 69.5 (41/59) |
| Stage III | 72.63 (51/70) | | 82.9 (58/70) |
| Stage IV | 72.2 (32/44) | | 87.8 (36/41) |

**Table 4 Relationship between MEK and ERK protein expression and clinicopathological features of colorectal cancer patients**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **General data** |  | **MEK protein** | | | **ERK protein** | | |
| **Positive rate (%)** | ***P-*value** | ***χ²*** | **Positive rate (%)** | ***P-*value** | ***χ²*** |
| Median age (yr) | <56 | 62.9 (44/70) | 0.097 | 0.756 | 46.5 (33/71) | 0.822 | 0.365 |
|  | ≥56 | 65.1 (82/126) | 53.2 (66/124) |
| Gender | Male | 68.1 (77/113) | 1.728 | 0.189 | 51.3 (58/113) | 0.034 | 0.855 |
| Female | 59.0 (49/83) | 50 (41/82) |
| Differentiation | Medium-low | 64.5(100/155) | 0.017 | 0.896 | 46 (69/150) | 6.012 | 0.015 |
| Well | 63.4 (26/41) | 66.7 (30/45) |
| Infiltration depth | T1 + T2 | 68.4 (26/38) | 0.356 | 0.553 | 51.4 (19/37) | 0.006 | 0.937 |
| T3 + T4 | 63.3 (100/158) | 48.2 (80/166) |
| Lymph node metastasis | N0 | 63.0 (58/92) | 0.117 | 0.733 | 47.8 (44/92) | 0.604 | 0.437 |
| N1-N3 | 65.4 (68/104) | 53.4 (55/103) |
| Distant metastasis | M0 | 60.3 (91/151) | 4.631 | 0.031 | 49 (74/151) | 0.832 | 0.362 |
| M1 | 77.8 (35/45) | 56.8 (25/44) |
| TNM stage | I | 72 (18/25) | 5.89 | 0.117 | 52.0 (13/25) | 2.435 | 0.487 |
| II | 57.9 (33/57) | 43.63 (25/57) |
| III | 58.6 (41/70) | 50 (35/70) |
| IV | 77.3 (34/44) | 59.1 (26/44) |

**Table 5 Relationship between *KRAS* genotype and expression of downstream proteins in colorectal cancer tissues**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Protein** | ***KRAS* mutant type group**  **positive rate** | | ***KRAS* wild-type group**  **positive rate** | ***χ²*** | ***P-*value** |
|  |
| BRAF | | 74.2% (46/62) | 74.6% (100/134) | 0.004 | 0.948 |
| MEK | | 54.8% (34/62) | 58.2% (78/134) | 0.196 | 0.657 |
| ERK | | 45.2% (28/62) | 54.1% (72/133) | 1.364 | 0.243 |

**Table 6 Correlation between the expression of KRAS and downstream proteins**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Protein** | | **KRAS protein**  **positive group** | **KRAS protein negative group** | ***χ²*** | ***P-*value** |
| BRAF | 76.4% (107/140) | | 69.6% (39/56) | 0.964 | 0.325 |
| MEK | 78.6% (99/126) | | 58.6% (41/70) | 8.775 | 0.003 |
| ERK | 69.6% (78/112) | | 39.3% (22/56) | 4.298 | 0.038 |

**Table 7 Correlation between expression of BRAF and downstream proteins**




|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Protein** | **BRAF protein positive group** | **BRAF protein negative group** | ***χ²*** | ***P-*value** |
| MEK | 67.5% (96/146) | 60.0% (30/50) | 0.534 | 0.464 |
| ERK | 52.7% (77/146) | 46% (23/50) | 0.674 | 0.411 |

**Table 8 Relationship between progression-free survival and KRAS, BRAF, MEK, and ERK protein expression**





|  | **B** | **SE** | **Wald** | **df** | **Sig.** | **Exp (B)** | **95.0%CI of Exp (B)** | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Lower limit** | **Upper limit** |
| KRAS | 1.200 | 0.506 | 5.623 | 1 | 0.018 | 3.319 | 1.231 | 8.944 |
| MEK | -0.872 | 0.609 | 2.054 | 1 | 0.152 | 0.418 | 0.127 | 1.378 |
| ERK | -0.480 | 0.507 | 0.898 | 1 | 0.343 | 0.619 | 0.229 | 1.670 |
| BRAF | 0.031 | 0.581 | 0.003 | 1 | 0.958 | 1.031 | 0.330 | 3.221 |
| T |  |  | 4.609 | 3 | 0.203 |  |  |  |
| T1 | 1.330 | 1.160 | 1.317 | 1 | 0.251 | 3.783 | 0.390 | 36.714 |
| T2 | -0.780 | 0.858 | 0.827 | 1 | 0.363 | 0.458 | 0.085 | 2.463 |
| T3 | 0.664 | 0.522 | 1.617 | 1 | 0.203 | 1.943 | 0.698 | 5.408 |
| N | -0.018 | 0.485 | 0.001 | 1 | 0.970 | 0.982 | 0.380 | 2.541 |





**Table 9 Relationship between overall survival and KRAS, BRAF, MEK, and ERK protein expression**





|  | **B** | **SE** | **Wald** | **df** | **Sig.** | **Exp (B)** | **95.0%CI of Exp (B)** | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Lower limit** | **Upper limit** |
| KRAS | 0.360 | 0.536 | 0.452 | 1 | 0.501 | 1.434 | 0.501 | 4.101 |
| MEK | -0.736 | 0.585 | 1.586 | 1 | 0.208 | 0.479 | 0.152 | 1.506 |
| ERK | -0.571 | 0.501 | 1.303 | 1 | 0.254 | 0.565 | 0.212 | 1.507 |
| BRAF | 0.246 | 0.539 | 0.208 | 1 | 0.648 | 1.279 | 0.444 | 3.680 |
| T |  |  | 1.733 | 3 | 0.630 |  |  |  |
| T1 | 1.141 | 1.114 | 1.050 | 1 | 0.306 | 3.131 | 0.353 | 27.776 |
| T2 | -0.356 | 0.696 | 0.261 | 1 | 0.609 | 0.701 | 0.179 | 2.742 |
| T3 | 0.230 | 0.562 | 0.168 | 1 | 0.682 | 1.259 | 0.418 | 3.789 |
| N | 0.230 | 0.503 | 0.209 | 1 | 0.647 | 1.259 | 0.470 | 3.373 |







**Figure 1 Real-time polymerase chain reaction detection of mutated *KRAS* in formalin-fixed paraffin-embedded colorectal cancer tissues.** Left to right representative amplification plots for samples with wild-type, uncertain mutation status, and mutated *KRAS* genes.









**Figure 2 Expression of RAS pathway proteins in colorectal cancer.** A-D: KRAS negative (A and B) and positive (C and D) expression at magnification × 40 (A and C) and × 100 (B and D). E-P: As described for (A-D), except that staining for BRAF protein (E-H), MEK protein (I-L), and ERK protein (M-P) is shown.



**Figure 3 Effect of *KRAS* gene status on expression of KRAS protein on the cell membrane.** H-score: Histochemistry score.



**Figure 4 Effect of *KRAS* gene status on expression of KRAS protein in the cytoplasm.** H-score: Histochemistry score.



**Figure 5 Effect of *KRAS* gene status on BRAF protein expression.** H-score: Histochemistry score.



**Figure 6 Effect of *KRAS* gene status on MEK protein expression.** H-score: Histochemistry score.



**Figure 7 Effect of *KRAS* gene status on ERK protein expression.** H-score: Histochemistry score.



**Figure 8 Effect of RAS pathway protein expression on progression-free survival and overall survival in patients with stage II/III colorectal cancer.** A-H: Effects of KRAS (A and B), BRAF (C and D), MEK (E and F), and ERK (G and H) protein expression on progression-free survival (A, C, E, and G) and overall survival (B, D, F, and H). PFS: Progression-free survival; OS: Overall survival.